The Latest Breaking News on Pharma

Imagine, if you will, a small plastic baggy containing a mixture of crystals and powder.

While national efforts to eliminate hepatitis C have faced setbacks because of increased drug use, the impact of COVID-19 and insurance complications, there’s a bright spot: Some states are now making it easier for patients to treat the disease.

Abbott Laboratories is building a new infant-formula manufacturing plant after the product shortage of the past year revealed gaps in U.S. production capacity.

The Food and Drug Administration has authorized a booster dose of the COVID-19 vaccine made by Novavax

Drug addicts need treatment, as Peter Bensinger rightfully pointed out, but he is badly mistaken to think that the criminalization of drug sales and possession are also deterrents.

Pfizer’s (PFE) co-developed COVID-19 vaccine booster for children, which recently got Emergency Use Authorization from the U.S. FDA, could boost its share price. The stock had witnessed significant attention during the pandemic and could still be worth owning. Let’s discuss this in detail….

NYC and Cambridge-based Empyrean Neuroscience Inc. is a new genetic engineering company developing neuroactive compounds for neuropsychiatric and neurological disorders launching with a $22 million Series A financing.

The California Cannabis Industry Association (CCIA), a trade group representing hundreds of companies participating in the United States’ largest regulated cannabis market, has released a white paper entitled “Pandora’s Box: The Dangers of a National, Unregulated, Hemp-Derived Intoxicating Cannabinoid Market.&

An FDA advisory panel voted 14-1 on Wednesday to recommend that the agency withdraw its approval of the drug Makena, saying the treatment does not appear to reduce the risk of preterm birth.

Amid the macroeconomic issues and rampant volatility in the market, investor sentiment toward biotech stocks is declining. Many companies in this space are planning layoffs to reduce expenses. Amid the grim backdrop, we think investors should drop fundamentally weak biotech stocks Ginkgo Bioworks Holdings (DNA) and Immunic (IMUX) from their…

There are fears of a "twindemic" of Covid and flu this winter